WinstonWınston
Igene Biotechnology logo

Igene Biotechnology

IGNE
Agricultural Inputs · Basic Materials
Price
$0.00
+0.00 (+0.00%)
Market Cap
$15,654
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1600.4% over 6y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 90.4M (2003) → 1.54B (2009)

Igene Biotechnology is a small company that makes natural colorants and nutritional ingredients using fermentation technology. Its main product is astaxanthin, a pink-red pigment used in fish and shrimp farming to give salmon and other seafood their characteristic color. The company sells primarily to aquaculture producers and animal feed manufacturers.

Igene generates revenue by selling these fermentation-derived ingredients directly to feed and food producers. It operates as a niche player in the agricultural inputs market, competing against larger chemical and biotech companies that produce synthetic or algae-based astaxanthin. The company is small, with a market cap near zero and negative operating margins, meaning it currently spends more than it earns. The key challenge ahead is scaling production and cutting costs enough to compete on price with established rivals, while the broader growth opportunity lies in rising global demand for natural, non-synthetic feed additives in aquaculture.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-500.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$2M/ year

Rising (+12% vs prior year)

46.8% of revenue

15.6x the sector average (3%)

Investing heavily in future products and technology

Insider Activity

17.9%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$269,290 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Igene Biotechnology is putting 47% of revenue into R&D and that number is rising. That's 15.6x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
-23.6%
Weak — -23.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-99.9%
Shrinking sales (-99.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-35669.2%
Burning cash (-35669.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial